S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

IPO Filing: Zogenix, Inc. (ZGNX)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Zogenix, Inc. filed last night to come public via an initial public offering of up to $86.25 million in securities sales.  The company has applied to take the ticker "ZGNX" on NASDAQ.  Banc of America has been listed as the lead manager in the deal, with co-managers listed as Leerink Swann, Thomas Weisel Partners, and Susquehanna Financial Group.

It has two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Its lead product candidate, sumatriptan DosePro™, enables needle-free subcutaneous delivery of  sumatriptan for the treatment of acute migraine. Zogenics has submitted a New Drug Application FDA, for sumatriptan DosePro in December 2007, which was accepted for filing in March 2008. The company intends to build a focused sales force in the United States and launch the product in the first quarter of 2009. Its second product candidate is ZX002, a controlled release formulation of hydrocodone for the treatment of chronic pain. This ZX002 product candidate has completed Phase II clinical trials, and it anticipates initiating the Phase III clinical program in the second half of 2008.

As the company is still in development stage, it essentially has no real revenues.  The San Diego-based company was formed in May, 2006 as SJ2 Therapeutics, Inc. but changed its name to Zogenix, Inc. when it commenced operations on August 25, 2006.  Its trademarks include DosePro™, Intraject® and Zogenix™.

Jon C. Ogg
March 21, 2008

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Chris Lange |

Axsome Therapeutics Files for IPO

Axsome Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Axsome Therapeutics Sets Terms for IPO
Chris Lange |

Axsome Therapeutics Sets Terms for IPO

Axsome Therapeutics expects to price more than 4 million shares in the range of $11 to $13 in an IPO…
Urovant Closes in on IPO
Chris Lange |

Urovant Closes in on IPO

Clinical-stage biopharmaceutical company Urovant Sciences intends to price 10 million shares for an initial public offering valued up to $184…
Chris Lange |

The Gamble That Did Not Pay Off

Zogenix has announced an agreement for the sale of its Zohydro ER (hydrocodone bitartrate) business to Pernix for $100 million.
Reata Pharma Fills in the Blanks for Its IPO
Chris Lange |

Reata Pharma Fills in the Blanks for Its IPO

Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Harpoon Therapeutics Files for IPO
Chris Lange |

Harpoon Therapeutics Files for IPO

Clinical-stage immunotherapy company Harpoon Therapeutics has filed with the SEC for its initial public offering.
Douglas A. McIntyre |

IPO Filings: Phenomix; MYR Group

PHENOMIX CORP. submitted an IPO filing last Friday. The filing shows for a sale of up to $86,250,000 in securities,…
Selecta Biosciences Files for IPO: Targeting Gout
Jon C. Ogg |

Selecta Biosciences Files for IPO: Targeting Gout

Selecta Biosciences has filed its paperwork with the Securities and Exchange Commission to conduct an initial public offering (IPO) ahead.…
Chris Lange |

Aimmune Prepares For IPO By Setting Expected Price Range

ThinkstockAimmune Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering. The…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618